Three questions for IMW CNE from Joseph D. Tariman's lecture (Per Beth Faiman's request)
1. Genomics is a rapidly changing science with unprecedented discoveries in the past decades. Which of the following statements of the patient requires further teaching by the nurse on the basics of genomics?
A. In the genome sequences, alterations in the DNA sequence are called single nucleotide poymorphisms (SNPs) and they occur when a single nucleotide (A, T, G, or C) is broken.
B. There are many variations in genetic sequences that may play a role in differences in health.
C. An estimated 1.42 million SNPs have been identified in the human genome.
D. Not a single, specific SNP has been evaluated in patients with myeloma for risk detection of the …show more content…
Which of the following statements are false regarding the use of genomic data during myeloma-related treatment decision making? SELECT ALL THAT APPLY:
A. The use of genomic data during myeloma treatment decision making is widely variable from practice to practice.
B. Academic-based practice are more likely to use genomic data than private practices during myeloma treatment decision making.
C. Community-based practices lag behind in adapting genomic-based myeloma treatment decisions.
D. Myeloma genomic data are not mature enough for translation to practice.
ANSWER: B, C, D (Rationale: B and C have no research data to support those statements; D is false because Mayo Clinic has already implemented the mSMART protocol to all their clinic sites and mSMART is a risk-adaptive treatment algorithm based on genomic data; the other commercially available genomic testing for myeloma is MyPRS for gene expression profiling or GEP. MyPRS is now increasingly utilized/translated into practice).
3. As a nurse caring for a newly diagnosed myeloma patient with deletion of chromosome 17 and translocation (14;16), which of the following patient needs would you prioritize?
A. Advanced directives
B. Pharmacological
C. Safety
D.